NIKKEI 225
27,883.78 +365.53 (+1.33%) HANG SENG
20,192.40 +407.75 (+2.06%) CRUDE OIL
73.10 -0.10 (-0.14%) GOLD FUTURES
1,967.60 -5.90 (-0.30%) DOW
32,608.14 +213.89 (+0.66%) BTC-GBP
22,925.32 +1,138.56 (+5.23%)
OSE Immunotherapeutics SA (0RAD.L)
| Previous close | 9.50 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 66.833M |
| Beta (5Y monthly) | 1.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.06 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology
NANTES, France, March 15, 2023--OSE Immunotherapeutics to Present Preclinical and Clinical Research Updates from its Pipeline and Platforms in Immuno-Oncology At the 2023 AACR
- Business Wire
OSE Immunotherapeutics Receives New Approval for an Early Access Program for Tedopi® in Spain in Non-Small Cell Lung Cancer After Failure to Immunotherapies
NANTES, France, March 01, 2023--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that the Spanish Drug Agency (Agencia Espanola de Medicamentos y Productos Sanitarios, AEMPS) has made available a new early access program that will allow access to Tedopi® through a Special Situation Authorization(1) in the treatment of advanced or metastatic non-small cell lung (NSCLC) after immune checkpoint inhibitor (ICI) failure. This Special Situation Au
- Business Wire
OSE Immunotherapeutics Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology
NANTES, France, February 22, 2023--OSE Immuno Updates on Anti-IL-7 Receptor Antagonist OSE-127/S95011, a Breakthrough Approach in Chronic Inflammatory Autoimmune Diseases and Hematology
